Warning letterPosted December 16, 2025
FDA warning letter to 3D Imaging Drug Design and Development LLC
CGMP/Positron Emission Tomography (PET) Drugs/Adulterated
FDA posted a warning letter to 3D Imaging Drug Design and Development LLC on December 16, 2025; the letter is dated December 4, 2025. Subject: CGMP/Positron Emission Tomography (PET) Drugs/Adulterated. Issuing office: Center for Drug Evaluation and Research (CDER).
On the record
- Company
- 3D Imaging Drug Design and Development LLC
- Subject
- CGMP/Positron Emission Tomography (PET) Drugs/Adulterated
- Issuing office
- Center for Drug Evaluation and Research (CDER)
- Letter dated
- 2025-12-04
- Posted by FDA
- 2025-12-16
- Source
- FDA warning letters ↗
CFR cited
The record cites 4 sections of 21 CFR Parts 207 and 212.
The full record
An account shows the violations FDA described and each CFR section it cited.
What a warning letter is
A warning letter is FDA's notice to a company that it found significant violations of federal requirements. FDA asks for a written response, normally within 15 working days. The letter is advisory: it states the agency's position and is not a final agency action.
More
Watch 3D Imaging Drug Design and Development LLC
A free account shows the last 7 days of every record. Pro adds a watchlist: one email when FDA acts on a company you name.
From FDA warning letters. The record may have changed since it was read.
Approve Suite is not affiliated with FDA, or with 3D Imaging Drug Design and Development LLC.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.